Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has reported a loss for its first fiscal quarter (ending March 31) of $-0.52 versus a loss $-1.40 for the same period a year ago. This result was in line with the consensus estimate of $-0.52. For the latest four quarters through March 31, E.P.S. were $-2.65 compared to $-8.69 a year ago.
Recent Price Action
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) stock closed at $150.31 on 5/2/24 after a slight gain of 0.2%. This advance was accompanied by normal trading volume. The stock has risen 4.5% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, ALNY is expected to be a major Value Eraser.
Alnylam Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment